The NewBiologix team has extensive expertise in deciphering and harnessing genomic information to understand, engineer and significantly improve cell line capabilities for the expression and production of advanced therapy medicinal products (ATMPs).
Next-generation sequencing (NGS)-based genome characterization is used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through different NGS-based technologies involving short reads, long reads and optical mapping allowing for exceptionally in-depth datasets composed of a high-coverage sequence assembly. The combination of these technologies enables the exploration of biological systems at multiple levels, ranging from genomic to epigenetic and transcriptomic. Including NGS during the cell line development process allows to make data-driven decisions on the stability, integrity, and biosafety of cell banks and provides robust supportive data for regulatory submissions.
